440 related articles for article (PubMed ID: 25788198)
1. New cellular and molecular targets for the treatment of portal hypertension.
Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology and a Rational Basis of Therapy.
Gracia-Sancho J; Maeso-Díaz R; Bosch J
Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
[TBL] [Abstract][Full Text] [Related]
3. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.
Bosch J; Abraldes JG; Fernández M; García-Pagán JC
J Hepatol; 2010 Sep; 53(3):558-67. PubMed ID: 20561700
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies for portal hypertension in cirrhosis.
Nair H; Berzigotti A; Bosch J
Expert Opin Emerg Drugs; 2016 Jun; 21(2):167-81. PubMed ID: 27148904
[TBL] [Abstract][Full Text] [Related]
5. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
Tsai HC; Li TH; Huang CC; Huang SF; Liu RS; Yang YY; Hsieh YC; Lee KC; Huang YH; Hou MC; Lin HC
Am J Pathol; 2018 Jul; 188(7):1608-1624. PubMed ID: 29929914
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
Tripathi DM; Vilaseca M; Lafoz E; Garcia-Calderó H; Viegas Haute G; Fernández-Iglesias A; Rodrigues de Oliveira J; García-Pagán JC; Bosch J; Gracia-Sancho J
Gastroenterology; 2018 Nov; 155(5):1564-1577. PubMed ID: 30055171
[TBL] [Abstract][Full Text] [Related]
7. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic management of portal hypertension.
Berzigotti A; Bosch J
Clin Liver Dis; 2014 May; 18(2):303-17. PubMed ID: 24679496
[TBL] [Abstract][Full Text] [Related]
9. Infection as a Trigger for Portal Hypertension.
Steib CJ; Schewe J; Gerbes AL
Dig Dis; 2015; 33(4):570-6. PubMed ID: 26159275
[TBL] [Abstract][Full Text] [Related]
10. Comparative portal hypotensive effects as propranolol of vitamin D₃ treatment by decreasing intrahepatic resistance in cirrhotic rats.
Lee PC; Yang YY; Lee WP; Lee KC; Hsieh YC; Lee TY; Lin HC
J Gastroenterol Hepatol; 2015 Mar; 30(3):628-37. PubMed ID: 25187428
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment of portal hypertension.
González-Abraldes J; Bosch J; García-Pagán JC
Curr Opin Investig Drugs; 2001 Oct; 2(10):1407-13. PubMed ID: 11890356
[TBL] [Abstract][Full Text] [Related]
12. [The application of non-selective β-blockers, angiotensin receptor antagonists and statins in liver cirrhotic patients].
Zhang XX; Guo JS
Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):923-928. PubMed ID: 31941254
[TBL] [Abstract][Full Text] [Related]
13. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
[TBL] [Abstract][Full Text] [Related]
15. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.
Bosch J; Groszmann RJ; Shah VH
J Hepatol; 2015 Apr; 62(1 Suppl):S121-30. PubMed ID: 25920081
[TBL] [Abstract][Full Text] [Related]
16. Biology of portal hypertension.
McConnell M; Iwakiri Y
Hepatol Int; 2018 Feb; 12(Suppl 1):11-23. PubMed ID: 29075990
[TBL] [Abstract][Full Text] [Related]
17. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
18. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.
Gunarathne LS; Rajapaksha H; Shackel N; Angus PW; Herath CB
World J Gastroenterol; 2020 Oct; 26(40):6111-6140. PubMed ID: 33177789
[TBL] [Abstract][Full Text] [Related]
19. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of portal hypertension.
Iwakiri Y
Clin Liver Dis; 2014 May; 18(2):281-91. PubMed ID: 24679494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
